ArticleCJC pediatric and congenital heart disease2025
The Role of Medical Therapy in Management of Bicuspid Aortic Valve-Associated Aortopathy in Children.
Article in CJC pediatric and congenital heart disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with bicuspid aortic valve (BAV) are often treated with medication to slow the rate of aortic dilatation, without established efficacy. Methods: We conducted a retrospective, multicentre study of 558 children (83 treated and 475 not treated) with BAV and ascending aorta (AscAo) dilatation. The median follow-up was 3.6 years for treated patients and 5.6 years for not treated patients. Longitudinal mixed models assessed the rate of AscAo and sinus of Valsalva (SoV) dilatation expressed as a change in Results: Compared with untreated patients, those treated had a small reduction of AscAo and SoV dilatation rates with an absolute treatment difference of -0.032 Conclusion: Pharmacologic treatment was not associated with a meaningful reduction of AscAo and SoV dilatation rates in children with BAV.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.